



Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş.
İstanbul Trakya Serbest Bölgesi,
Ferhatpaşa SB Mahallesi
Atatürk Bulvarı No:16 34540
Çatalca-İstanbul
Türkiye

Your ref.

Our ref.

Tel.

Fax

E-mail

CA-2023-173

+31 88 96 83009

+31 88 96 83100

medical.nl@dekra.com

Arnhem, 23 May 2023, revised 8 June 2023, revised 5 July 2023

Subject: Extension of validity of DEKRA Certification B.V. Certification Agreement for continuation of MDD 93/42/EEC or AIMD 90/385/EEC surveillance activities, in reference to Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulation (EU) 2017/745 as regards the transitional provision for certain medical devices

Dear Mrs Kantar,

Introduction:

Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulation (EU) 2017/745 and (EU) 2017/746 as regards the transitional provision for certain medical devices and in vitro diagnostic medical devices has been published on 20 March 2023 and came into force on the same day.

This Regulation (EU) 2023/607 has amended Regulation (EU) 2017/745 (from here referred to as MDR 2017/745) to now identify that under certain conditions certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC that were still valid on 26 May 2021 and that have not been withdrawn afterwards shall remain valid after the end of the period indicated on the certificate under certain conditions. Additionally should the manufacturer intend to make use of the extension of the validity of the certificates, involvement of a notified body for continued surveillance is required.

This agreement identifies the devices and certificates for which the required conditions are met and that the manufacturer intends to make use of the options for extension of the validity of the certificates. The agreement also identifies the conditions under which DEKRA Certification B.V. will be the notified body responsible for continued surveillance. In order for DEKRA Certification

B.V. to continue these surveillance activities the Certification Agreement in place with the manufacturer will be extended, as detailed further below.

Agreement:

Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. has identified the intention to make use of the options for extension of the validity of the certificates as detailed in the amendment of the MDR 2017/745 by Regulation (EU) 2023/607.

Evidence has been provided by Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. that they meet the following condition(s) for the certificates issued by DEKRA Certification B.V. in accordance with Directives 90/385/EEC and/or 93/42/EEC to remain valid:

- Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. holds certificates issued by DEKRA Certification B.V. in accordance with Directives 90/385/EEC and/or 93/42/EEC that were still valid on 26 May 2021 and that have not been withdrawn afterwards and were not expired on 20 March 2023 and:
 - (a) Has already lodged a formal application with a notified body in accordance with MDR 2017/745 Section 4.3, first subparagraph, of Annex VII for conformity assessment in respect of the device or in respect of the device intended to substitute that device.

A written agreement in accordance with MDR 2017/745 Section 4.3, second subparagraph, of Annex VII, is already in place between the notified body to which the formal application has been made and Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş.

Based on evidence provided by Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. it has been determined that the following 90/385/EEC and/or 93/42/EEC DEKRA Certification B.V. certificates of Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. for the devices indicated below meet the requirements to remain valid:

Certificate number	Scope and product categories	MDD, Annex	Class & rule	Expiration date of Certificate
2161507DE04	Cardiovascular Guiding Catheters • Alviguides™ Blue+ Interventional Cardiology Guiding Catheter	II	III, Rule 6	1 June 2023
2161507CE02	Medical devices for cardiovascular interventions applications: • Cardiovascular Guiding Catheters: Alviguides™ Blue+ Interventional Cardiology Guiding Catheter • PTCA Balloon Dilatation Catheters: Invader™ PTCA Balloon Dilatation Catheter • Cardiovascular Angiographic Catheters: Alvision™ Interventional Cardiology Diagnostic Catheter	II	III, Rue 6	1 June 2023
2161507DE01	PTCA Balloon Dilatation Catheters • Invader™ PTCA Balloon Dilatation Catheter	II	III, rule 6	1 June 2023
2161507DE03	Cardiovascular Angiographic Catheters • Alvision™ Interventional Cardiology Diagnostic Catheter	II	III, rule 6	1 June 2023

By signing this agreement Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. also confirms that the following additional requirements of MDR 2017/745 Article 120 3c, as amended by Regulation (EU) 2023/607, are met, and will continue to be met, for all products listed above which will continue to be placed on the market:

- those devices continue to comply with Directive 90/385/EEC or Directive 93/42/EEC, as applicable;
- there are no significant changes in the design and intended purpose;
- the devices do not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health;

Additionally Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. also commits that no later than 26 May 2024, the manufacturer has put in place a quality management system in accordance with MDR 2017/745 Article 10(9).

Following from the above information and commitments from Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. DEKRA Certification B.V. agrees to be the notified body responsible for the continued appropriate surveillance in accordance with applicable requirements, and in the respect of the applicable devices identified above, as stipulated in MDR 2017/745 Article 120 3e,

as amended by Regulation (EU) 2023/607, DEKRA Certification B.V.. This appropriate surveillance shall include at least:

- Surveillance audits in accordance with Directive 90/385/EEC or Directive 93/42/EEC (as applicable), considering also MDR 2017/745 requirements for post market surveillance, vigilance, registration of economic operators and of devices as required by MDR 2017/745 Article 120
- Assessment of reportable changes
- Assessment of reportable adverse events (vigilance) for impact on certification status

For the specific devices given above for which the certificate can still be considered valid, the certificate validity date and dates until when the products may be placed on the market or put into service are as follows.

Type of Device	Date until which certificate can still be considered valid
Class III Class IIb implantable devices excluding well-established technologies (sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)	31 December 2027
Class IIb devices Class IIb implantable devices which are well-established technologies (sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors) Class IIa devices Class I sterile devices Class I devices with a measuring function	31 December 2028

The table above thus also defines the dates until which DEKRA Certification B.V. is responsible for the appropriate surveillance, unless one of the following situations applies:

- Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. provides a Notification of Change to inform DEKRA Certification B.V. that devices will no longer be placed on the market or put into service and the certificate should no longer be considered to be valid
- DEKRA Certification B.V. is not the notified body with which the written agreement has been signed for conformity assessment of the device or substitute device in accordance with MDR 2017/745. In this case the notified body with which the written agreement has been signed for conformity assessment of the device or substitute device must take responsibility for surveillance of the device which has a certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC. This should be no later than 26 September 2024 as detailed in MDR 2017/745 Article 120 3e, as amended by





Regulation (EU) 2023/607. Thus DEKRA Certification B.V.'s responsibility for surveillance will end on 26 September 2024 in this case, or before if a Notification of Change is provided to confirm that the surveillance activities are now carried out by another Notified Body.

Finally, by signing this agreement DEKRA Certification B.V. and Alvimedica Tıbbi Ürünler San.ve Dış Tic. A.Ş. agree that current **Certification Agreement CA 23-149** which covers the products under the Directive 90/385/EEC and/or Directive 93/42/EEC certificates listed above will thus continue to remain valid until the dates as stipulated above, in order for DEKRA Certification B.V. to meet the required surveillance responsibilities. This also includes that the manufacturer will continue to meet the following responsibilities as stipulated in that Certification Agreement:

- Allowing DEKRA to carry out appropriate surveillance activities in respect of the applicable requirements
- Reporting of significant changes to DEKRA Certification B.V. for assessment
- Reporting of adverse events (vigilance) to DEKRA Certification B.V. for assessment

Should you agree with the above please confirm this through a signature below.

Thus duly agreed, drafted and signed:

Company Name

DEKRA Certification B.V.

Alvimedica Tıbbi Ürünler
(place)

Arnhem
(place)

Gatakarı İSTANBUL-Türkiye
(date)

5 July 2023
(date)

05.07.2023

ALVIMEDICA TIBBİ ÜRÜNLER
SAN. VE DİŞ TİC. A.Ş.
İstanbul Trakya Serbest Bölgesi Ferhatpaşa Şb.
Atatürk Bulvarı No: 10 Gatakarı / İstanbul
Tel: 0212 786 60 60 Faks: 0212 786 60 90
Büyükcemal V.D. 031 054 67 48
Mersis No: 0833054674000016
(signature)

(signature)

Ahmet Özcan
(name)

B.T.M. Holtus
(name)

Board Member
(title)

Managing Director
(title)